# Leap Therapeutics Inc. (LPTX)

Source: https://www.quantisnow.com/company/LPTX
Generated: 2026-11-17T13:11:42.833Z

- Ticker: LPTX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: leaptx.com

## About

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

## Latest LPTX news and filings

- 2025-11-13 22:02 UTC [SEC Form 4] [SEC Form 4 filed by CEO,CFO,Pres.,GC,Treas.&Sec. Onsi Douglas E](https://www.quantisnow.com/insight/sec-form-4-filed-by-ceocfopresgctreassec-onsi-douglas-e-6278205)
- 2025-11-13 22:01 UTC [SEC Form 4] [SEC Form 4 filed by Director Li William](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-li-william-6278201)
- 2025-11-13 21:59 UTC [SEC Form 4] [SEC Form 4 filed by Director Richard Christian M](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-richard-christian-m-6278156)
- 2025-11-13 21:58 UTC [SEC Form 4] [SEC Form 4 filed by Director Mashiach Nissim](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mashiach-nissim-6278136)
- 2025-11-13 21:58 UTC [SEC Form 4] [SEC Form 4 filed by Director Martin Patricia A.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-martin-patricia-a-6278127)
- 2025-11-13 21:56 UTC [SEC Form 4] [SEC Form 4 filed by Director Schilsky Richard](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-schilsky-richard-6278121)
- 2025-11-13 21:56 UTC [SEC Form 4] [SEC Form 4 filed by Director Loscalzo Joseph](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-loscalzo-joseph-6278117)
- 2025-11-13 21:55 UTC [SEC Form 4] [SEC Form 4 filed by Director Cavanaugh James H](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-cavanaugh-james-h-6278113)
- 2025-11-13 21:54 UTC [SEC Form 4] [SEC Form 4 filed by Director Mirabelli Christopher](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-mirabelli-christopher-6278110)
- 2025-11-13 21:54 UTC [SEC Form 4] [SEC Form 4 filed by Director Dietz Thomas John](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-dietz-thomas-john-6278097)
- 2025-11-13 21:53 UTC [SEC Form 4] [SEC Form 4 filed by Director Oei Khing Djien](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-oei-khing-djien-6278096)
- 2025-11-13 21:52 UTC [SEC Form 3] [SEC Form 3 filed by new insider Oei Khing Djien](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-oei-khing-djien-6278080)
- 2025-11-12 21:10 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Leap Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-leap-therapeutics-inc-6274532)
- 2025-11-12 21:06 UTC [SEC Form 8-K] [Leap Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement](https://www.quantisnow.com/insight/leap-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6274398)
- 2025-11-12 14:13 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Leap Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-leap-therapeutics-inc-6273403)
- 2025-11-12 13:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Leap Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-leap-therapeutics-inc-6273052)
- 2025-11-12 13:10 UTC [SEC Form 8-K] [Leap Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Other Events](https://www.quantisnow.com/insight/leap-therapeutics-inc-filed-sec-form-8-k-amendments-to-articles-6273032)
- 2025-11-12 13:00 UTC [Mergers & Acquisitions] [Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results](https://www.quantisnow.com/insight/cypherpunk-technologies-formerly-leap-therapeutics-reports-third-quarter-2025-financial-6272966)
- 2025-11-12 12:00 UTC [Leadership Update] [Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy](https://www.quantisnow.com/insight/leap-therapeutics-rebrands-as-cypherpunk-expands-leadership-team-to-drive-6272659)
- 2025-11-03 13:44 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Leap Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-leap-therapeutics-inc-6255740)
- 2025-11-03 13:39 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Leap Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-leap-therapeutics-inc-6255728)
- 2025-10-24 20:58 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Leap Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-leap-therapeutics-inc-6244814)
- 2025-10-20 12:49 UTC [SEC Form 8-K] [SEC Form 8-K filed by Leap Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-leap-therapeutics-inc-6238392)
- 2025-10-20 11:00 UTC [Mergers & Acquisitions] [Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025](https://www.quantisnow.com/insight/leap-therapeutics-presents-final-data-from-defiance-study-at-esmo-6237993)
- 2025-10-09 11:00 UTC [Public Offering] [Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy](https://www.quantisnow.com/insight/leap-therapeutics-announces-closing-of-5888-million-private-placement-in-6228255)
- 2025-10-09 11:09 UTC [SEC Form 8-K] [Leap Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events](https://www.quantisnow.com/insight/leap-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6228254)
- 2025-10-06 13:08 UTC [SEC Form 8-K] [Leap Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/leap-therapeutics-inc-filed-sec-form-8-k-other-events-6224190)
- 2025-10-06 13:00 UTC [Mergers & Acquisitions] [Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy](https://www.quantisnow.com/insight/leap-therapeutics-announces-5888-million-private-placement-in-cash-commitments-6224180)
- 2025-09-25 11:00 UTC [Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025](https://www.quantisnow.com/insight/leap-therapeutics-to-present-final-clinical-data-from-part-b-6211289)
- 2025-09-11 20:31 UTC [SEC Form 8-K] [Leap Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/leap-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6198167)
- 2025-08-14 21:28 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Leap Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-leap-therapeutics-inc-6167212)
- 2025-08-14 11:11 UTC [SEC Form 8-K] [Leap Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/leap-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6164391)
- 2025-08-14 11:00 UTC [Dividends] [Leap Therapeutics Reports Second Quarter 2025 Financial Results](https://www.quantisnow.com/insight/leap-therapeutics-reports-second-quarter-2025-financial-results-6164343)
- 2025-08-14 10:50 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Leap Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-leap-therapeutics-inc-6164292)
- 2025-07-01 20:31 UTC [SEC Form 4] [SEC Form 4 filed by Chief Scientific Officer Baum Jason](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-scientific-officer-baum-jason-6106202)
- 2025-07-01 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Chief Operating Officer Lawlor Augustine](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-operating-officer-lawlor-augustine-6106181)
- 2025-07-01 20:30 UTC [SEC Form 4] [SEC Form 4 filed by Chief Manufacturing Officer O'Mahony John Mark](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-manufacturing-officer-omahony-john-6106154)
- 2025-06-23 11:15 UTC [SEC Form 8-K] [Leap Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/leap-therapeutics-inc-filed-sec-form-8-k-costs-associated-with-6094807)
- 2025-06-23 11:00 UTC [Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives](https://www.quantisnow.com/insight/leap-therapeutics-reports-updated-clinical-data-from-sirexatamab-colorectal-cancer-6094773)
- 2025-05-13 11:10 UTC [SEC Form 8-K] [Leap Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/leap-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6034614)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/LPTX
- Earnings history: https://www.quantisnow.com/earnings/LPTX
- Dividend history: https://www.quantisnow.com/dividends/LPTX
- Insider transactions: https://www.quantisnow.com/insiders/LPTX
- Options chain: https://www.quantisnow.com/options/LPTX
- SEC 8-K filings only: https://www.quantisnow.com/company/LPTX/8-k
- RSS and alerts for LPTX: https://www.quantisnow.com/docs/rss-feeds.md
